Pharming Group (PHAR) Scheduled to Post Quarterly Earnings on Wednesday

Pharming Group (NASDAQ:PHAR) is scheduled to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.01 per share for the quarter.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.08). The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Pharming Group Stock Performance

NASDAQ:PHAR opened at $10.00 on Monday. Pharming Group has a 52 week low of $9.27 and a 52 week high of $16.71. The firm has a 50-day moving average price of $10.70 and a two-hundred day moving average price of $11.36. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 14th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.